Last €0.75 EUR
Change Today -0.0005 / -0.07%
Volume 102.7K
PRL On Other Exchanges
Symbol
Exchange
BrsaItaliana
As of 11:30 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

pierrel spa (PRL) Snapshot

Open
€0.74
Previous Close
€0.75
Day High
€0.75
Day Low
€0.74
52 Week High
04/8/14 - €0.85
52 Week Low
11/15/13 - €0.49
Market Cap
37.1M
Average Volume 10 Days
689.4K
EPS TTM
€-0.59
Shares Outstanding
49.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PIERREL SPA (PRL)

Related News

No related news articles were found.

pierrel spa (PRL) Related Businessweek News

No Related Businessweek News Found

pierrel spa (PRL) Details

Pierrel S.p.A. provides contract research and manufacturing services to the pharmaceutical and life science industries. It primarily manufactures local dental anesthetic drug cartridges. The company is involved in the development of various types of drugs, such as tube vials, bottles, ampoules, drops, sprays, syrups, gels, creams, ointments, and tablets; and production of active ingredients, including active substances and pharmaceutical formulations. It also provides consulting and operational services for the research and development of new molecules and drug products; and consulting services for clinical and regulatory development programs, as well as operational services for the execution of international phase I-IV, late phase, and non-interventional clinical trials. The company operates in the United States, Australia, Canada, Russia, and the Middle East. Pierrel S.p.A. is based in Milan, Italy.

pierrel spa (PRL) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: €82.9K
Compensation as of Fiscal Year 2012.

pierrel spa (PRL) Key Developments

Pierrel S.p.A. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2013; Revises Earnings Guidance for the Year 2013

Pierrel S.p.A.reported consolidated earnings results for the nine months ended September 30, 2013. For the period, the company reported net loss of EUR 10.6 million against EUR 6.7 million a year ago. Revenues dropped by 35.2% annually and amounted to EUR 21.5 million. The operating loss widened by 88.6% to EUR 9.1 million. For the year 2013, the company revised its end year targets with expected revenues for EUR 30 million, down from an earlier forecast of EUR 42 million and a gross operating loss of EUR 7.9 million, against a EUR 2.63 million loss estimated previously. .

Pierrel SpA and Benco Dental Sign Orabloc Distribution Deal for the USA

Pierrel SpA has signed a deal with Benco Dental to distribute its Orabloc dental anaesthetic in the United States. Pierrel, which signed the distribution agreement via its subsidiary Pierrel Pharma Srl, will thus have access to some 90% of the US dental market for selling its Orabloc anaesthetic.

Pierrel SpA Signs Distribution Agreement with Henry Schein Inc to Distribute its Orabloc Dental Anaesthetic in the USA and Canada

Pierrel SpA has signed a distribution agreement with dental and medical products distributor Henry Schein Inc. to distribute its Orabloc dental anaesthetic in the USA and Canada. With the distribution deal Pierrel will have access to 90% of the Canadian dental market and 75% of the US dental market, said the Italian company which signed the agreement via its Pierrel Pharma Srl.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRL:IM €0.75 EUR -0.0005

PRL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRL.
View Industry Companies
 

Industry Analysis

PRL

Industry Average

Valuation PRL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PIERREL SPA, please visit www.pierrel.it. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.